A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 3, 2007, Pages 293-301

  Rugino, Thomas ^a  

^a Children's Specialized Hospital   (United States)

Author keywords

Adolescents; Attention deficit hyperactivity disorder; Behavior; Children; Modafinil; Treament

Indexed keywords

AMPHETAMINE; CONTRACEPTIVE AGENT; CYCLOSPORIN; DIAZEPAM; MEPHENYTOIN; METHYLPHENIDATE; MODAFINIL; PEMOLINE; PHENYTOIN; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; AGGRESSION; ANOREXIA; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILD CARE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ERYTHEMA MULTIFORME; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HUMAN; INSOMNIA; MANIA; NERVOUSNESS; PSYCHOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STRUCTURE ANALYSIS; SUICIDAL IDEATION; TABLET FORMULATION; WEIGHT REDUCTION;

EID: 34547680517     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Akaoka H, Roussel B, Lin JS, et al. 1991. Effect of modafinil and amphetamine on the ratcatecholinergic neuron activity. Neurosci Lett, 123:20-2.
2. Arnsten AF. 2006. Stimulants:Therapeutic actions in ADHD. Neuropsychopharmacology, E-pub ahead of print.
3. Biederman J, Swanson JM, Wigal SB, et al. 2005. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder:results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics, 116:e777-84.
4. Biederman J, Swanson JM, Wigal SB, et al. 2006. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry, 67:727-35.
5. Brown RT, Antler RW, Freeman WS, et al. 2005. Treatment of attention-deficit/hyperactivity disordenoverview of the evidence. Pediatrics, 115:049-57.
6. Bush G, Frazier JA, Rauch SL, et al. 1999. Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol Psychiatry, 45:1542-52.
7. Chemelli RM, Willie JT, Sinton CM, et al. 1999. Narcolepsy in orexin knock-out mice:molecular genetics of sleep regulation. Cell, 98:409-12.
8. Cephalon, Inc. 2004. Prescribing Information:Provigil (Modafinil) Tablets PR0542. West Chester, PA:Cephalon, Inc.
9. Cephalon, Inc. 2006. Modafinil (CEP- 1538) tablets Supplemental NDA 20-717/S-019 ADHD Indication:briefing document for Psychopharmacologic Drugs Advisory Committee Meeting. Frazer, PA: Cephalon, Inc.
10. Cohen J. 1998. Statistical power analysis for the behavioral sciences (2nd ed). Hillsdale, New Jersey: Lawrence Eribaum Associates.
11. Conners CK. 2000. Conners Parent Rating Scales - Revised: Technical Manual. North Tonawanda, NY. Multi-Health Systems, Inc.
12. DePaul G, Power TJ, Anastopoulos AD, et al. 1998. ADHD Rating Scale - IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford Publications.
13. Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, et al. 2002. Study of the addictive potential of modafiniA in naive and cocaine-experienced rats. Psychopharmacology, 161:387-95.
14. DeSereville JE, Boer C, Rambert FA, et al. 1994. Lack of pre-synaptic dopaminergic involvement in modafinil activity in anesthetized mice: in vivo voltammetry studies. Neuropharmacology, 33:755-61.
15. Ellis CM, Monk A, Simmons G, et al. 1999. Functional magnetic resonance imaging neuroactivation studies in normal subjects and subjects with the narcoleptic syndrome. Actions of modafinil. J Sleep Res, 8: 95.
16. Ferraro L, Antonelli T, O'Connor WT, et al. 1997. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry, 42:1181-3.
17. Gallopin T, Luppi PH, Rambert FA, et al. 2004. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep, 27:19-25.
18. Gelpirin K. 2006. Psychiatric adverse events with drug treatment of ADHD. Presentation to the Pediatric Advisory Committee to the United States Food and Drug Administration; March 22, 2006 [online]. Accessed August 24, 2006. URL: http://www.fda.gov/ohrms/dockets/ac/06/slides/ 2006-4210s-index.htm.
19. Gold LH, Balster RL. 1996. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology, 126:296-92.
20. Greenhill LL, Biederman J, Boellner SW, et al. 2006. A randomized, double-blind, placebo-controlled study of modafinil film-coated. tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psych, 45:503-11.
21. Gresham FK Elliot SN. 1990. Social Skills Rating System Manual. Circle Pines: Minnesota: American Guidance Service.
22. Jasinski DR. 2000. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol, 14:53-60.
23. Jasinski DR, Lovacevic-Ristanovic R. 2000. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol, 23:149-56.
24. King S, Griffin S, Hodges Z, et al. 2006. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamme and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess, 10:1-162.
25. Kucsmarski RJ, Ogden CL, Grummer-Strawn LM, et al. 2000. CDC Growth Charts: United States. Adv Data, 314:1-27.
26. Lin JS, Hou Y, Jouvet M. 1996. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA, 93:14128-33.
27. Lin JS, Roussel B, Akaoka H, et al. 1992. Role of catecholamines in the modafinil and amphetamine induced wakeftilness, a comparative pharmacological study in the cat. Brain Res, 591:319-26.
28. Mignot E, Nishino S, Guillemunault C, et al. 1994. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep, 17:436-7.
29. Myrick H, Malcolm R, Taylor B, et al. 2004. Modafinil: preclinical, clinical, and post-marketing surveillance - a review of abuse liability issues. Ann Clin Psychiatry, 16:101-9.
30. Rugino TA, Copley TC. 2001. Effects of modafinil in children with attention-deficit/hyperactivity disorder:an open-label study. J Am Acad Child Adolesc Psych, 40:230-235.
31. Rugino TA, Samsock TC. 2003. Modafinil in children with ADHD:a double blind, placebo controlled randomized study. Pediatr Neurol, 29:136-42.
32. Rush CR, Kelly TH, Hays LR, et al. 2002a. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol, 12:105-15.
33. Rush CR, Kelly TH, Hays LR, et al. 2002b. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend, 67:311-22.
34. Scammell TE, Estabrooke IV, McCarthy MT, et al. 2000. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci, 20:8620-8.
35. Shaffer D, Fisher P, Lucas CP, et al. 2000. NIMH Diagnostic Interview Schedule for Children version IV (NIMH DISC-IV):description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psych, 39:28-38.
36. Shelton J, Nishino S, Vaught J, et al. 1995. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep, 18:817-26.
37. Simon P, Hemet C, Ramassamy C, et al. 1995. Non-amephtaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol, 5:509-14.
38. Spence SA, Green RD, Wilkinson ID, et al. 2005. Modafinil modulates anterior cingulate ftinction in chronic schizophrenia. Br J Psychiatry, 187:55-61.
39. Swanson JM, Castellanos FX, Murias M, et al. 1998. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr Opin Neurobiol, 8:263-71.
40. Swanson JM, Greenhill LL, Lopez FA, et al. 2006. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry, 67:137-47.